Graves' Disease Symptoms: Hyperthyroidism and Eye Changes

What is Graves' disease and why does it cause hyperthyroidism?

In Graves' disease, the immune system produces antibodies called thyroid-stimulating immunoglobulins (TSI). These antibodies bind to the same receptor on thyroid cells that TSH normally activates — but unlike TSH, they are not regulated by feedback. The result is continuous thyroid stimulation and overproduction of thyroid hormones (T3 and T4).

Graves' disease accounts for 60–80% of all hyperthyroidism cases in the United States 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy. It places Graves' in the autoimmune category alongside Hashimoto's thyroiditis, though the direction of effect is opposite: Graves' drives overactivity; Hashimoto's typically leads to underactivity over time. Both are more common in women and in people with a family history of thyroid disease 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy.

Autoimmune thyroid disease overall affects an estimated 5.2% of U.S. adults — approximately 11.6 million people — with women experiencing about twice the prevalence of men 2Ref 2Dillon CF, Weisman MH, Leung AM, Brent GA, Miller FW (2025).Autoimmune Thyroid Disease in the United States: Population Prevalence, Diagnosis Rates, and Trends.Autoimmune thyroid disease affects ~5.2% of U.S. adults (~11.6 million people); women experience about twice the prevalence of men. Blood tests in Graves' disease characteristically show a suppressed TSH and elevated free T4 or free T3; the TSI antibody test, when positive, is highly specific for Graves' 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy.

What are the most common symptoms of Graves' disease?

Symptoms reflect the effects of excess thyroid hormone on nearly every organ system:

Cardiovascular - Rapid or irregular heartbeat (palpitations, atrial fibrillation in more severe cases) - High blood pressure - Feeling warm or sweating excessively

Metabolic - Unintended weight loss despite eating normally or more than usual - Increased appetite - Frequent bowel movements or loose stools

Nervous system and mood - Tremor in the hands - Anxiety, irritability, or feeling wired and unable to settle - Difficulty concentrating - Insomnia

Muscular - Muscle weakness, particularly in the upper legs and arms (proximal myopathy) - Fatigue despite feeling restless

Skin and hair - Warm, moist, fine skin - Hair thinning - In a minority of patients, a skin thickening on the shins called pretibial myxedema

Reproductive - Irregular or lighter periods in women - Reduced fertility in severe, untreated disease

What makes Graves' disease different from other causes of hyperthyroidism?

Hyperthyroidism has several causes — toxic nodular goiter, thyroiditis, or excess thyroid medication — but Graves' disease accounts for the large majority of cases 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy.

The distinguishing features of Graves' specifically are: 1. Positive TSI or TRAb antibodies — these are not present in other causes of hyperthyroidism 2. Diffuse goiter — the entire thyroid is enlarged rather than a single nodule 3. Eye disease — Graves' ophthalmopathy (thyroid eye disease) affects roughly one-third to one-half of people with Graves' and does not occur in non-autoimmune hyperthyroidism 3Ref 3Wiersinga WM, Eckstein AK, Žarković M (2025).Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.TED predominantly mild in 77%, moderate-to-severe in 22%, sight-threatening in 1%; up to 5% of TED patients are euthyroid; teprotumumab FDA-approved for moderate-to-severe active TED 4. Risk of relapse after treatment — unlike toxic nodules, Graves' can go into remission spontaneously or with antithyroid drugs, but it can also relapse

A radioactive iodine uptake scan can confirm a diffusely overactive thyroid and help distinguish Graves' from other causes when antibodies alone are not conclusive 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy.

What are Graves' disease eye symptoms?

Graves' ophthalmopathy (also called thyroid eye disease or thyroid-associated orbitopathy) occurs when the same autoimmune process attacks the tissues behind and around the eyes. It predominantly affects people with Graves' hyperthyroidism but can also occur in euthyroid patients 3Ref 3Wiersinga WM, Eckstein AK, Žarković M (2025).Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.TED predominantly mild in 77%, moderate-to-severe in 22%, sight-threatening in 1%; up to 5% of TED patients are euthyroid; teprotumumab FDA-approved for moderate-to-severe active TED. Symptoms range from mild to severe:

• Eye dryness, grittiness, or irritation — often the earliest symptom
• Puffiness or swelling around the eyes — especially in the morning
• Stare or lid retraction — the eyelids pull back, giving a wide-eyed appearance
• Proptosis (bulging eyes, exophthalmos) — the eyeballs protrude forward as inflamed tissue pushes them outward
• Double vision (diplopia) — from swelling of the muscles that move the eyes
• Pain with eye movement
• In severe cases, vision changes — if the optic nerve is compressed, vision can be affected and requires urgent evaluation

Eye disease is predominantly mild in about 77% of cases, moderate-to-severe in 22%, and rarely sight-threatening in 1% 3Ref 3Wiersinga WM, Eckstein AK, Žarković M (2025).Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.TED predominantly mild in 77%, moderate-to-severe in 22%, sight-threatening in 1%; up to 5% of TED patients are euthyroid; teprotumumab FDA-approved for moderate-to-severe active TED. Eye involvement can appear before, during, or after thyroid disease is diagnosed, and its severity does not always correlate with how abnormal thyroid levels are. Smoking significantly worsens Graves' ophthalmopathy and increases the risk of severe eye disease 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy.

Severe or rapidly progressing eye symptoms should be evaluated promptly by an ophthalmologist with experience in thyroid eye disease, in addition to an endocrinologist.

How is Graves' disease diagnosed and managed?

Diagnosis is confirmed by the combination of suppressed TSH, elevated thyroid hormones, and either a positive TRAb/TSI antibody or classic eye findings.

Treatment options include 1Ref 1Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016).2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Graves' disease as the leading cause of hyperthyroidism (60–80% of cases), diagnostic criteria including TRAb antibodies, treatment options, and smoking worsening ophthalmopathy:

• Antithyroid medications (methimazole or propylthiouracil) — taken by mouth to reduce thyroid hormone production; first-line in many settings, with a remission rate of roughly 30–50% after 12–18 months of treatment
• Radioactive iodine (RAI) — taken by mouth; the thyroid absorbs it and is gradually destroyed; typically leads to hypothyroidism requiring lifelong levothyroxine afterward
• Thyroidectomy — surgical removal; preferred when there is a large goiter, suspected malignancy, or significant eye disease where RAI could worsen ophthalmopathy

Beta-blockers are often added early on to control heart rate and tremor while waiting for thyroid hormone levels to normalize. For moderate-to-severe active thyroid eye disease, teprotumumab (an IGF-1 receptor inhibitor) has been FDA-approved based on randomized trial evidence showing meaningful reductions in proptosis and diplopia 3Ref 3Wiersinga WM, Eckstein AK, Žarković M (2025).Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.TED predominantly mild in 77%, moderate-to-severe in 22%, sight-threatening in 1%; up to 5% of TED patients are euthyroid; teprotumumab FDA-approved for moderate-to-severe active TED.

Management is best done by an endocrinologist, often in coordination with an ophthalmologist if eye disease is present. Gale can help you prepare questions and find the right specialist.